Concepts (111)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hand Hygiene | 2 | 2019 | 12 | 0.650 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2019 | 148 | 0.580 |
Why?
|
| Bacterial Infections | 1 | 2019 | 304 | 0.520 |
Why?
|
| Anti-Bacterial Agents | 3 | 2019 | 2391 | 0.500 |
Why?
|
| Joint Prosthesis | 1 | 2013 | 12 | 0.450 |
Why?
|
| Shoulder Joint | 1 | 2013 | 24 | 0.440 |
Why?
|
| Infection Control | 1 | 2015 | 161 | 0.440 |
Why?
|
| Aortitis | 1 | 2013 | 6 | 0.430 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2013 | 93 | 0.420 |
Why?
|
| Haemophilus Infections | 1 | 2013 | 92 | 0.410 |
Why?
|
| Haemophilus influenzae | 1 | 2013 | 130 | 0.410 |
Why?
|
| Meningitis | 1 | 2013 | 99 | 0.410 |
Why?
|
| Guideline Adherence | 1 | 2015 | 376 | 0.400 |
Why?
|
| Cross Infection | 1 | 2015 | 331 | 0.380 |
Why?
|
| Prosthesis-Related Infections | 1 | 2013 | 176 | 0.380 |
Why?
|
| Marfan Syndrome | 1 | 2013 | 137 | 0.370 |
Why?
|
| Kidney Failure, Chronic | 1 | 2019 | 862 | 0.370 |
Why?
|
| Escherichia coli Infections | 1 | 2013 | 191 | 0.370 |
Why?
|
| Aorta, Thoracic | 1 | 2013 | 517 | 0.300 |
Why?
|
| Vibrio vulnificus | 1 | 2005 | 4 | 0.250 |
Why?
|
| Vibrio Infections | 1 | 2005 | 16 | 0.250 |
Why?
|
| Fallopian Tube Diseases | 1 | 2005 | 12 | 0.240 |
Why?
|
| Ovarian Diseases | 1 | 2005 | 27 | 0.240 |
Why?
|
| Ribavirin | 1 | 2004 | 79 | 0.230 |
Why?
|
| Granuloma | 1 | 2004 | 69 | 0.230 |
Why?
|
| Interferons | 1 | 2004 | 120 | 0.230 |
Why?
|
| Abscess | 1 | 2005 | 138 | 0.220 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2004 | 147 | 0.210 |
Why?
|
| Hepatitis C | 1 | 2004 | 368 | 0.180 |
Why?
|
| Disease Notification | 1 | 2020 | 7 | 0.180 |
Why?
|
| Antiviral Agents | 1 | 2004 | 736 | 0.170 |
Why?
|
| Patient Isolation | 1 | 2019 | 15 | 0.160 |
Why?
|
| Disinfection | 1 | 2019 | 25 | 0.160 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2022 | 441 | 0.150 |
Why?
|
| Influenza Vaccines | 1 | 2022 | 469 | 0.140 |
Why?
|
| Respiratory Tract Infections | 1 | 2020 | 263 | 0.140 |
Why?
|
| Antimicrobial Stewardship | 1 | 2019 | 84 | 0.140 |
Why?
|
| Catheter-Related Infections | 1 | 2019 | 129 | 0.140 |
Why?
|
| Influenza, Human | 1 | 2022 | 646 | 0.130 |
Why?
|
| Disease Eradication | 1 | 2015 | 34 | 0.120 |
Why?
|
| Ebolavirus | 1 | 2015 | 45 | 0.120 |
Why?
|
| Pneumonia | 1 | 2019 | 325 | 0.120 |
Why?
|
| Hemorrhagic Fever, Ebola | 1 | 2015 | 57 | 0.120 |
Why?
|
| Hemolysin Proteins | 1 | 2014 | 31 | 0.120 |
Why?
|
| Urinary Tract Infections | 1 | 2019 | 289 | 0.120 |
Why?
|
| Pneumonia, Ventilator-Associated | 1 | 2014 | 41 | 0.120 |
Why?
|
| Sepsis | 1 | 2019 | 478 | 0.120 |
Why?
|
| Synovial Fluid | 1 | 2013 | 15 | 0.110 |
Why?
|
| Shoulder Dislocation | 1 | 2013 | 8 | 0.110 |
Why?
|
| Disease Outbreaks | 1 | 2015 | 319 | 0.110 |
Why?
|
| Bacterial Toxins | 1 | 2014 | 176 | 0.110 |
Why?
|
| Arthroplasty, Replacement | 1 | 2013 | 23 | 0.110 |
Why?
|
| Debridement | 1 | 2013 | 85 | 0.110 |
Why?
|
| Prosthesis Failure | 1 | 2013 | 156 | 0.100 |
Why?
|
| Humans | 13 | 2022 | 122412 | 0.100 |
Why?
|
| Pandemics | 1 | 2020 | 1103 | 0.100 |
Why?
|
| Immunocompromised Host | 1 | 2014 | 300 | 0.100 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2014 | 220 | 0.100 |
Why?
|
| Radiography, Thoracic | 1 | 2013 | 156 | 0.100 |
Why?
|
| Middle Aged | 5 | 2020 | 25588 | 0.100 |
Why?
|
| Renal Dialysis | 1 | 2019 | 842 | 0.100 |
Why?
|
| Female | 9 | 2022 | 64939 | 0.090 |
Why?
|
| Staphylococcus aureus | 1 | 2014 | 457 | 0.090 |
Why?
|
| Diagnostic Imaging | 1 | 2013 | 269 | 0.090 |
Why?
|
| Anti-Infective Agents | 1 | 2013 | 266 | 0.090 |
Why?
|
| Reoperation | 1 | 2013 | 807 | 0.090 |
Why?
|
| Staphylococcal Infections | 1 | 2014 | 552 | 0.080 |
Why?
|
| Diagnosis, Differential | 1 | 2013 | 1874 | 0.070 |
Why?
|
| Aspergillus flavus | 1 | 2005 | 2 | 0.070 |
Why?
|
| Scleritis | 1 | 2005 | 9 | 0.070 |
Why?
|
| Aspergillosis | 1 | 2005 | 42 | 0.060 |
Why?
|
| Peptides, Cyclic | 1 | 2005 | 53 | 0.060 |
Why?
|
| Treatment Outcome | 3 | 2013 | 12035 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2013 | 2035 | 0.060 |
Why?
|
| Eye Infections, Fungal | 1 | 2005 | 77 | 0.060 |
Why?
|
| Triazoles | 1 | 2005 | 138 | 0.060 |
Why?
|
| Drainage | 1 | 2005 | 254 | 0.050 |
Why?
|
| RNA, Messenger, Stored | 1 | 2022 | 7 | 0.050 |
Why?
|
| Pyrimidines | 1 | 2005 | 375 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2013 | 3456 | 0.050 |
Why?
|
| Drug Therapy, Combination | 1 | 2005 | 1146 | 0.050 |
Why?
|
| Vaccines, Synthetic | 1 | 2022 | 312 | 0.050 |
Why?
|
| Epidemiological Monitoring | 1 | 2020 | 59 | 0.040 |
Why?
|
| Seasons | 1 | 2020 | 300 | 0.040 |
Why?
|
| Adult | 3 | 2022 | 28743 | 0.040 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2020 | 516 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2005 | 2813 | 0.030 |
Why?
|
| Liberia | 1 | 2015 | 8 | 0.030 |
Why?
|
| Poverty Areas | 1 | 2015 | 30 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2005 | 4984 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2005 | 3306 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2022 | 3231 | 0.030 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2014 | 28 | 0.030 |
Why?
|
| Aged | 2 | 2020 | 18779 | 0.030 |
Why?
|
| Fiber Optic Technology | 1 | 2014 | 46 | 0.030 |
Why?
|
| Bronchi | 1 | 2014 | 100 | 0.030 |
Why?
|
| Bronchoscopy | 1 | 2014 | 155 | 0.030 |
Why?
|
| Prevalence | 1 | 2020 | 2369 | 0.030 |
Why?
|
| Texas | 1 | 2020 | 3508 | 0.020 |
Why?
|
| Health Personnel | 1 | 2015 | 500 | 0.020 |
Why?
|
| Pregnancy | 1 | 2022 | 7101 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2020 | 6303 | 0.020 |
Why?
|
| United States | 1 | 2022 | 10475 | 0.020 |
Why?
|
| Lung | 1 | 2014 | 1486 | 0.020 |
Why?
|
| Lipopeptides | 1 | 2005 | 33 | 0.020 |
Why?
|
| Voriconazole | 1 | 2005 | 35 | 0.020 |
Why?
|
| Echinocandins | 1 | 2005 | 44 | 0.020 |
Why?
|
| Antifungal Agents | 1 | 2005 | 293 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2020 | 15879 | 0.010 |
Why?
|
| Male | 2 | 2020 | 59581 | 0.010 |
Why?
|
| Animals | 1 | 2014 | 33898 | 0.010 |
Why?
|